Phase 2 Prostate Cancer Trial, Recruiting NCT06854250 Sponsor: Sun Yat-sen University Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06854250
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between 18 and 80 years old
  • People whose prostate cancer has been confirmed by a tissue sample (biopsy) as a specific type called acinar adenocarcinoma
  • People whose prostate cancer had already spread to other parts of the body at the time it was first diagnosed, based on standard staging guidelines
  • People whose cancer had not gotten worse by the time the prostate freezing treatment (cryoablation) was started
  • People who are in generally good physical health and able to carry out daily activities with little or no limitation (confirm with trial site what this means for your situation)
  • People who are well enough to safely undergo general anaesthesia and the prostate freezing procedure
  • People without significant abnormalities in their test results (confirm with trial site for specific details)
  • People who are able to understand the study information and sign a consent form

Who may not be able to join:

  • People with a serious illness that makes the planned treatment unsuitable for them
  • People who have had another type of cancer in the past 5 years, except for certain common skin cancers (non-melanoma skin cancer)
  • People who have already received treatments other than those specified in this trial's treatment plan
  • People whose prostate cancer has grown into the rectum
  • People whose prostate remains larger than 55ml after 6 months of hormone therapy (androgen deprivation therapy)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-1390229060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
1 March 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PSA progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov